Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Dow
Mallinckrodt
AstraZeneca
Harvard Business School

Last Updated: August 11, 2022

Investigational Drug Information for RO7034067


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for RO7034067?

RO7034067 is an investigational drug.

There have been 6 clinical trials for RO7034067. The most recent clinical trial was a Phase 1 trial, which was initiated on October 20th 2016.

The most common disease conditions in clinical trials are Muscular Atrophy, Spinal, Muscular Atrophy, and Atrophy. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].

There are two US patents protecting this investigational drug and eighty international patents.

Recent Clinical Trials for RO7034067
TitleSponsorPhase
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Ambulatory Children With Spinal Muscular AtrophyHoffmann-La RochePhase 2/Phase 3
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese ParticipantsHoffmann-La RochePhase 1
A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular AtrophyHoffmann-La RochePhase 2

See all RO7034067 clinical trials

Clinical Trial Summary for RO7034067

Top disease conditions for RO7034067
Top clinical trial sponsors for RO7034067

See all RO7034067 clinical trials

US Patents for RO7034067

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RO7034067 See Plans and Pricing Compounds for treating spinal muscular atrophy PTC Therapeutics, Inc. (South Plainfield, NJ) F. Hoffmann-La Roche AG (Basel, CH) See Plans and Pricing
RO7034067 See Plans and Pricing Compounds for treating spinal muscular atrophy HOFFMANN-LA ROCHE INC. (Little Falls, NJ) PTC THERAPEUTICS, INC. (South Plainfield, NJ) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RO7034067

Drugname Country Document Number Estimated Expiration Related US Patent
RO7034067 Argentina AR092794 2032-02-10 See Plans and Pricing
RO7034067 Australia AU2013216870 2032-02-10 See Plans and Pricing
RO7034067 Australia AU2017204248 2032-02-10 See Plans and Pricing
RO7034067 Brazil BR112014019750 2032-02-10 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Dow
Mallinckrodt
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.